16.67
price down icon4.58%   -0.80
pre-market  Vorhandelsmarkt:  17.67   1.00   +6.00%
loading
Schlusskurs vom Vortag:
$17.47
Offen:
$18.53
24-Stunden-Volumen:
172.18K
Relative Volume:
1.92
Marktkapitalisierung:
$153.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.17M
KGV:
-1.6449
EPS:
-10.1344
Netto-Cashflow:
$-82.84M
1W Leistung:
+2.05%
1M Leistung:
-4.42%
6M Leistung:
-73.64%
1J Leistung:
-72.65%
1-Tages-Spanne:
Value
$16.25
$19.03
1-Wochen-Bereich:
Value
$16.25
$20.11
52-Wochen-Spanne:
Value
$11.13
$98.00

Korro Bio Inc Stock (KRRO) Company Profile

Name
Firmenname
Korro Bio Inc
Name
Telefon
617-468-1999
Name
Adresse
60 FIRST STREET, CAMBRIDGE
Name
Mitarbeiter
104
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-08
Name
Neueste SEC-Einreichungen
Name
KRRO's Discussions on Twitter

Vergleichen Sie KRRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KRRO
Korro Bio Inc
16.67 153.37M 0 -81.17M -82.84M -10.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.50 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.91 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.51 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
257.19 30.64B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.77 27.24B 3.81B -644.79M -669.77M -6.24

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-16 Eingeleitet Chardan Capital Markets Buy
2025-01-10 Eingeleitet Oppenheimer Outperform
2024-10-21 Eingeleitet Raymond James Strong Buy
2024-08-14 Eingeleitet William Blair Outperform
2024-03-28 Bestätigt H.C. Wainwright Buy
2024-02-27 Eingeleitet BMO Capital Markets Outperform
2023-12-04 Eingeleitet H.C. Wainwright Buy
2023-11-29 Eingeleitet RBC Capital Mkts Outperform
2023-11-10 Eingeleitet Piper Sandler Overweight
2023-02-15 Herabstufung Chardan Capital Markets Buy → Neutral
2023-02-13 Herabstufung Cowen Outperform → Market Perform
2021-09-22 Herabstufung Goldman Buy → Neutral
2021-01-27 Hochstufung JP Morgan Neutral → Overweight
2020-12-22 Eingeleitet B. Riley Securities Buy
2020-07-14 Eingeleitet Oppenheimer Outperform
2020-05-18 Herabstufung JP Morgan Overweight → Neutral
2019-10-28 Eingeleitet Cowen Outperform
2019-10-28 Eingeleitet Goldman Buy
2019-10-28 Eingeleitet JP Morgan Overweight
Alle ansehen

Korro Bio Inc Aktie (KRRO) Neueste Nachrichten

pulisher
Apr 29, 2025

Cantor Fitzgerald sets $74 target on Korro Bio stock with Overweight rating - Investing.com

Apr 29, 2025
pulisher
Apr 19, 2025

Korro Bio (NASDAQ:KRRO) Research Coverage Started at Chardan Capital - Defense World

Apr 19, 2025
pulisher
Apr 16, 2025

Chardan sets $25 target on Korro Bio stock with Buy rating - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Chardan Initiates Korro Bio at Buy With $25 Price Target - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 16, 2025
pulisher
Apr 15, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by Wellington Management Group LLP - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Brokerages - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Purchases New Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Kemi Olugemo '87 Named Chief Medical Officer at Korro Bio - UMass Lowell

Apr 11, 2025
pulisher
Apr 09, 2025

Raymond James Financial Inc. Purchases New Shares in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Apr 09, 2025
pulisher
Apr 01, 2025

Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer - citybiz

Apr 01, 2025
pulisher
Apr 01, 2025

Korro Bio appoints new Chief Scientific Officer - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

RNA-Editing Pioneer Korro Bio Lands Elite CSO with 20+ Drug Development Success Record - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Swiss National Bank Acquires Shares of 10,000 Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 27, 2025

Korro Bio CFO Returns from Medical Leave - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Korro Bio reappoints CFO, names new principal accounting officer - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener

Mar 27, 2025
pulisher
Mar 25, 2025

HC Wainwright Has Negative Outlook for Korro Bio Q1 Earnings - The AM Reporter

Mar 25, 2025
pulisher
Mar 24, 2025

Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Korro Bio (KRRO) Gets a Buy from Piper Sandler - The Globe and Mail

Mar 24, 2025
pulisher
Mar 23, 2025

Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter

Mar 23, 2025
pulisher
Mar 22, 2025

HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Korro Bio Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo

Mar 19, 2025
pulisher
Mar 19, 2025

RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 19, 2025
pulisher
Mar 18, 2025

Korro Bio, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 15, 2025

FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

FDA grants orphan drug status to Korro’s AATD treatment - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times

Mar 14, 2025
pulisher
Mar 14, 2025

Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World

Mar 10, 2025
pulisher
Feb 26, 2025

Korro to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 26, 2025

Finanzdaten der Korro Bio Inc-Aktie (KRRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.79
price up icon 0.78%
$71.40
price up icon 2.20%
$32.71
price up icon 0.52%
$23.62
price down icon 2.03%
$104.00
price up icon 0.00%
biotechnology ONC
$249.77
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):